在慢性持续性喘治疗中添加白血球抗剂:一种随机双盲安慰剂对照试验
D S Robinson1, D Campbell, P J Barnes
1Allergy and Clinical Immunology, Imperial College School of Medicine at the National Heart and Lung Institute, London SW3 6LY, UK. d.s.robinson@ic.ac.uk
Lancet (London, England)
|July 5, 2001
概括
在一项随机试验中,蒙特卢卡斯特 (Montelukast),一种白血受体对抗剂,在添加到皮质类固醇治疗时,没有显著改善喘症状或肺功能. 这项研究发现,中度至重度喘患者没有额外的益处.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 列可素受体对抗剂 (LTRAs) 在改善肺功能和减少喘患者的皮质类固醇依赖方面表现有前途.
- 然而,它们作为已经服用皮质类固醇的患者的附加疗法的有效性需要进一步研究.
研究的目的:
- 为了评估蒙特卢卡斯特作为慢性喘症状患者的补充治疗的有效性,尽管目前的皮质类固醇治疗.
- 评估蒙特卢卡斯特对症状评分和肺功能的影响.
主要方法:
- 进行了一项双盲,安慰剂控制,随机交叉试验.
- 100名患有症状喘的吸入性皮质类固醇患者接受了10毫克蒙特卢卡斯特或安慰剂14天.
- 使用症状日记和峰值呼气流量 (PEF) 测量来收集结果数据.
主要成果:
- 72名患者完成了这项研究.
- 与安慰剂相比,蒙特卢卡斯特并没有导致症状得分,β (2) 激动剂使用或每天两次的峰值呼气流量的显著改善.
- 只有少数患者 (蒙特卢卡斯特治疗的4人与安慰剂治疗的7人) 符合基于PEF增加的治疗反应标准.
结论:
- 当蒙特卢卡斯特作为门诊治疗的附加疗法时,对于已经服用皮质类固醇的中度至重度喘患者没有提供显著的额外益处.
- 观察到的结果低于检测肺功能有意义变化的预期值.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.